Seems good. Few points.
A) I wonder why they would use a low dose of MPC's? From all the reports seen so far it appears that a heavy maximal dose produces the best results.
B) Later on in the report towards the bottom it quotes some impressive reading statistics. But at the beginning of the report it says "The trial investigators concluded that administration of a low MPC dose appeared to be safe and there was a potential signal of efficacy. "
Potential sign? Odd considering at the end of the report using their stats they basically make it clear (from their POV) there is no potential about it. Just seems odd.
Ann: Circulation Publishes Improved Outcomes with Mesoblast Cells, page-2
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
0.025(2.70%) |
Mkt cap ! $1.084B | |||
| Open | High | Low | Value | Volume |
| 94.0¢ | 96.8¢ | 93.5¢ | $4.207M | 4.417M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 42268 | 94.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.0¢ | 48002 | 3 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |